



AMENDMENTS TO THE CLAIMS

1. (Currently Amended) A method of treating kidney cancer in a mammal in need thereof ~~mammals~~, which comprises administering an effective amount of a compound of the formula (I)




or a salt thereof to said mammal ~~a mammal~~.

2. (Original) The treatment method of kidney cancer according to claim 1, wherein the compound of the formula (I) is a compound of the formula (II)




3. (Original) The treatment method of kidney cancer according to claim 1, wherein the mammal is a human.

4. (Currently Amended) A method of suppressing growth of a cancerous tumor of the kidney *in vivo* in a mammal in need thereof ~~mammals~~, which comprises administering an effective amount of a compound of the formula (I)



or a salt thereof to said mammal ~~a mammal~~.


5. (Original) The method of suppressing growth of the cancerous tumor of the kidney according to claim 4, wherein the compound of the formula (I) is a compound of the formula (II)



6. (Canceled)


7. (Currently Amended) The method of ~~claim 6~~ claim 4, wherein the *in vivo* means in a body of a human.

8. (Withdrawn) A therapeutic agent of kidney cancer, which comprises, as an active ingredient, a compound of the formula (I)



or a salt thereof.

9. (Withdrawn) The therapeutic agent according to claim 8, wherein the compound of the formula (I) is a compound of the formula (II)




10. (Withdrawn) The therapeutic agent according to claim 8, which has an antitumor activity *in vivo*.

11. (Withdrawn) The therapeutic agent according to claim 8, which is used for a human.


12. – 15. (Canceled)

16. (Withdrawn) A pharmaceutical composition for treating kidney cancer, which comprises a compound of the formula (I)



or a salt thereof, and a pharmaceutically acceptable carrier.

17. (Withdrawn) The pharmaceutical composition of claim 16, wherein the compound of the formula (I) is a compound of the formula (II)



18. (Withdrawn) The pharmaceutical composition of claim 16, which has an antitumor activity *in vivo*.

19. (Withdrawn) The pharmaceutical composition of claim 16, which is used for a human.

20. (Withdrawn) A commercial package comprising a pharmaceutical composition of any of claims 16 to 19 and a written matter associated therewith, the written matter stating that the pharmaceutical composition can or should be used for treating kidney cancer.